Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea ...
New infrastructure builds on Amazon Growth Lab's work helping brands refresh 10,000+ SKUs for stronger Rufus and COSMO readiness SAN DIEGO, CA / ACCESS Newswire / March 28, 2026 / Amazon Growth Lab, a ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...
The album features 13 tracks, including 12 newly composed songs and a bonus track, "Christmas Star," created for fans, marking his most extensive tracklist to date. Blending diverse styles such as cla ...
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents ...
Results HighlightsLeveraging the dual-drive strategy of "Globalisation" and "Mid-to-High-End", TCL Electronics has achieved quality growth in global business and continuously strengthened overall ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed ...
The move comes amid a broader shift in investor behavior. With interest rates remaining elevated across major economies and macro conditions becoming less predictable, market participants are increasi ...
JACKSONVILLE, FL / ACCESS Newswire / March 28, 2026 / Following the official 2026 season schedule announcement, driver Tommy Pintos is set to commence the second season in the McLaren Trophy America ...
Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results